Orexo commences patent infringement litigation against Actavis
ET | Source:Orexo AB
Uppsala, Sweden – June 27, 2014 – Orexo AB today announced that it has filed a
patent infringement action in United States District Court for the District of
Delaware, against Actavis Elizabeth LLC and its parent company Actavis, Inc.
The lawsuit was filed in response to an Abbreviated New Drug Application
(“ANDA”) filed by Actavis. In its application, Actavis seeks to market and sell
generic versions of Orexo’s patented ZUBSOLV® (buprenorphine and naloxone)
products in the U.S. prior to the expiration of Orexo’s U.S. Patents listed in
the FDA’s Orange Book. The listed patents in the Orange Book are U.S. patents,
8,454,996 (expiration September 2019), 8,470,361 (expiration October 2029) and
8,658,198 (expiration December 2027).
Because Orexo AB timely initiated a lawsuit against Actavis, the FDA is
statutorily precluded from approving Actavis´ ANDA for 30 months, or until a
district court decision finding the patents invalid or not infringed, whichever
occurs earlier. The 30 month stay period began as of the date Orexo AB received
the Notice Letter from Actavis that notified Orexo of the ANDA filing.
“The ZUBSOLV® products have a significant market potential and the ANDA filing
of generic versions could be expected. Orexo has since the development of the
ZUBSOLV® products was initiated, worked with leading internal and external
experts to ensure a solid patent portfolio to protect the products. We have full
confidence in our patents listed in FDAs Orange Book today and intend to defend
our rights vigorously.” said Nikolaj Sørensen, Orexo’s president and CEO.
For further information, please contact:
Nikolaj Sørensen, President and CEO, Orexo AB
Tel: +46-703 50 78 88, E-mail: firstname.lastname@example.org
About ZUBSOLV® Sublingual Tablets
ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII) are indicated
for the maintenance treatment of opioid dependence and should be used as part of
a comprehensive treatment plan, which includes counseling and psychosocial
support. Treatment should be initiated under the direction of physicians who are
certified under the Drug Addiction Treatment Act of 2000, and who have been
assigned a unique identification number (“X” number).
ZUBSOLV® sublingual tablets can be abused in a manner similar to other opioids,
legal or illicit. Clinical monitoring appropriate to the patient’s level of
stability is essential. Liver function tests should be monitored before and
during treatment. Children who take ZUBSOLV® sublingual tablets can have severe,
possibly fatal, respiratory depression. Emergency medical care is critical. Keep
ZUBSOLV® sublingual tablets out of the sight and reach of children.
Adverse events commonly observed with the sublingual administration of
buprenorphine/naloxone sublingual tablets during clinical trials and post
-marketing experience are headache, nausea, vomiting, hyperhidrosis,
constipation, signs and symptoms of withdrawal, insomnia, pain and peripheral
Further information on ZUBSOLV® sublingual tablets can be found at
About Orexo AB
Orexo is a specialty pharma company with commercial operations in the United
States and R&D in Sweden developing improved treatments using proprietary drug
delivery technology and commercial operations in the United States. The company
is commercializing its proprietary product, ZUBSOLV® sublingual tablets, for
maintenance treatment of opioid dependence, in the United States. The ZUBSOLV®
sublingual tablet is a novel formulation of buprenorphine and naloxone using
Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of
two approved and revenue generating products currently marketed under license in
the EU and US. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ
OMX Stockholm Exchange and its American Depositary Receipts (ADRs) trade on the
OTCQX marketplace in the U.S. under the symbol, “ORXOY”. The largest
shareholders are Novo A/S and HealthCap.
For information about Orexo, please visit www.orexo.com
Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act and/or the Securities Markets Act. The
information was submitted for publication at 08:00am CET on June 27, 2014.
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
2321 Rosecrans Avenue.
El Segundo, CA 90245 Phone: (800) 307-6627 Fax: (800) 307-3567
25 Basinghall Street,
London EC2V 5HA
UK Phone: +1 866-465-8454